Category Archives: Medicine Patent Pool

Six Indian pharma companies get new licences to supply generic drugs

Posted on July 19, 2016 by donttradeourlivesaway

By Shreerupa Mitra-Jha, Firstpost | July 8, 2016 The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of … Continue reading →

Posted in Generics, Hepatitis C, Medicine Patent Pool, Uncategorized | Leave a comment

GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries

Posted on April 8, 2016 by donttradeourlivesaway

Source: GSK Press Release, 31 March 2016 Adopts approach to intellectual property reflecting a country’s economic maturity Will not file for patent protection in Least Developed and Low Income Countries Will seek to grant licences to generic manufacturers to supply … Continue reading →

Posted in IP Rights, LDCs, Medicine Patent Pool, Patent, Uncategorized | Leave a comment

The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

Posted on December 8, 2015 by donttradeourlivesaway

Medicines Patent Pool; December 1, 2015. Geneva – The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The … Continue reading →

Posted in HIV/Aids, Medicine Patent Pool, Public research | Leave a comment

KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)

Posted on November 30, 2015 by donttradeourlivesaway

Knowledge Ecology International, November 23, 2015. Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine … Continue reading →

Posted in Hepatitis C, Medicine Patent Pool | Leave a comment

The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine daclatasvir

Posted on November 30, 2015 by donttradeourlivesaway

PR Newswire; November 23, 2015. Geneva – The Medicines Patent Pool (MPP) today announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of … Continue reading →

Posted in Hepatitis C, Medicine Patent Pool | Leave a comment

The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

Posted on November 10, 2015 by donttradeourlivesaway

Medicines Patent Pool; November 6, 2015. Geneva – The Medicines Patent Pool (MPP), the world’s only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines.

Posted in Medicine Patent Pool, Voluntary License | Leave a comment

WikiLeaks shines rare light onto US trade negotiations

Posted on November 14, 2013 by donttradeourlivesaway

Source: Aljazeera America Leak details intellectual property rights deal in Trans-Pacific Partnership under negotiation between US and 10 nations US President Barack Obama poses for a photograph with Trans-Pacific Partnership leaders. In its latest document dump, WikiLeaks unearthed what it … Continue reading →

Posted in Generics, IP Rights, IPR Enforcement, Medicine Patent Pool, Pricing, Right to Health, TPP, Transparency | Tagged , , | Leave a comment

How drug companies price patients out of survival

Posted on November 7, 2013 by donttradeourlivesaway

Source: Salon As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another health care battle rages in village clinics and corporate boardrooms. Behind the seductive commercials for breakthrough treatments, multinational brands … Continue reading →

Posted in Compulsory Licensing, Data Exclusivity, EU-India FTA, Evergreening, Generics, HIV/Aids, Indian Patent Law, IP Rights, IPR Enforcement, Medicine Patent Pool, NAFTA, Novartis Case, Patent examination system, Patents, Right to Health, Sec 3 (d), TPP, Trade Agreements, TRIPS, TRIPS flexibilities, Tuberculosis (TB), WHO, WTO | Tagged , | Leave a comment

If You Can’t Join ‘Em, Beat ‘Em: New Industry Effort A Jab At Patent Pool?

Posted on June 22, 2012 by donttradeourlivesaway

Source: IP Watch Published on 21 June 2012 A new pharmaceutical industry initiative aimed at improving access to HIV treatments in least-developed countries is raising questions as to how it will fit with the Medicines Patent Pool, an existing group … Continue reading →

Posted in Medicine Patent Pool | Tagged , , , , | Leave a comment

Middle Income Countries, the new target for Big Pharma

Posted on August 8, 2011 by donttradeourlivesaway

ALCS Morocco & Act Up-Paris call on concerned countries to issue compulsory licencing without delay Casablanca • Paris —  A report released by MSF two weeks ago shows that the main pharmaceutical companies that hold most of the patents on … Continue reading →

Posted in Compulsory Licensing, Medicine Patent Pool | Tagged , | 1 Comment